association
Full identifier: http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association
Searching for classes...
Searching for instances...
Searching for templates...
Minted in Nanopublication
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAZ3PbvqVK...#association
This association
http://www.w3.org/2000/01/rdf-schema#label
has label
(this is a literal)
"opdivo is a programmed death receptor 1 pd 1 blocking antibody indicated for the treatment of 1 1 1 2 1 3 a 1 4 1 5 1 5 a 1 6 1 7 a 1 8 a 1 9 a 1 1 a opdivo as a single agent or in combination with ipilimumab is indicated for the treatment of patients with unresectable or metastatic melanoma opdivo is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection opdivo is indicated for the treatment of patients with metastatic non small cell lung cancer nsclc with progression on or after platinum based chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving opdivo opdivo is indicated for the treatment of patients with metastatic small cell lung cancer sclc with progression after platinum based chemotherapy and at least one other line of therapy this indication is approved under accelerated approval based on overall response rate and duration of response see clinical studies 14 4 opdivo in combination with ipilimumab is indicated for the treatment of patients with intermediate or poor risk previously untreated advanced rcc opdivo is indicated for the treatment of adult patients with classical hodgkin lymphoma chl that has relapsed or progressed after autologous hematopoietic stem cell transplantation hsct and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hsct this indication is approved under accelerated approval based on overall response rate see clinical studies 14 6 opdivo is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck scchn with disease progression on or after platinum based therapy opdivo is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who this indication is approved under accelerated approval based on tumor response rate and duration of response see clinical studies 14 8 opdivo as a single agent or in combination with ipilimumab is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high msi h or mismatch repair deficient dmmr metastatic colorectal cancer crc that has progressed following treatment with a fluoropyrimidine oxaliplatin and irinotecan this indication is approved under accelerated approval based on overall response rate and duration of response see clinical studies 14 9 opdivo is indicated for the treatment of patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib this indication is approved under accelerated approval based on tumor response rate and durability of response see clinical studies 14 1"
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAZ3PbvqVK...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
has drug
https://identifiers.org/drugbank:DB09035
drugbank:DB09035
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAZ3PbvqVK...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
has disease
http://purl.obolibrary.org/obo/DOID_3908
DOID_3908
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAZ3PbvqVK...#association
This association
https://w3id.org/biolink/vocab/relation
has relation
https://schema.org/TreatmentIndication
An indication for treating an underlying condition.
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAZ3PbvqVK...#association
This association
https://w3id.org/biolink/vocab/association_type
has BioLink type
https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation
ChemicalToDiseaseOrPhenotypicFeatureAssociation
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAZ3PbvqVK...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
has type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
association Statement
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAZ3PbvqVK...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
has predicate
https://w3id.org/biolink/vocab/treats
treats
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAZ3PbvqVK...#association
This association
https://w3id.org/biolink/vocab/provided_by
is provided by
https://w3id.org/um/NeuroDKG
NeuroDKG
.
This is the identifier for the assertion of this nanopublication.
http://purl.org/np/RAZ3PbvqVK...#assertion
The assertion above
http://www.w3.org/ns/prov#wasAttributedTo
is attributed to
https://orcid.org/0000-0002-1468-3557
me (Leoni Bücken)
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAZ3PbvqVK...
This nanopublication
http://purl.org/dc/terms/creator
is created by
https://orcid.org/0000-0002-1468-3557
me (Leoni Bücken)
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAZ3PbvqVK...
This nanopublication
date and time when the nanopublication was created
http://purl.org/dc/terms/created
was created on
(this is a literal)
"2021-07-03T15:33:18.413+02:00"
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAZ3PbvqVK...
This nanopublication
links to the assertion template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
was created from the assertion template
http://purl.org/np/RAManV5GZI...
RAManV5GZI
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAZ3PbvqVK...
This nanopublication
links to the provenance template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
was created from the provenance template
http://purl.org/np/RANwQa4ICW...
RANwQa4ICW
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAZ3PbvqVK...
This nanopublication
links to the publication info template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
was created from the publication info template
http://purl.org/np/RAA2MfqdBC...
RAA2MfqdBC
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAZ3PbvqVK...#sig
sig
http://purl.org/nanopub/x/hasSignatureTarget
has as target
This is the identifier for this whole nanopublication.
http://purl.org/np/RAZ3PbvqVK...
this nanopublication
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAZ3PbvqVK...#sig
sig
http://purl.org/nanopub/x/hasAlgorithm
has the algorithm
(this is a literal)
"RSA"
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAZ3PbvqVK...#sig
sig
http://purl.org/nanopub/x/hasPublicKey
has the public key
(this is a literal)
"MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAZ3PbvqVK...#sig
sig
http://purl.org/nanopub/x/hasSignature
has the signature
(this is a literal)
"FH3USB3QOaerGJmhx4XzZ2b28e0UBIIXQ0gXfqpfTG3WyAA85sGaiH6DahAGZiyUXgSjpOw6u6UZNYcOBzfuxftlF1oTZ5Kyc+ZPHjGTO0him3fJoQU//DIVmZQ+Pw0BtaWIf3SETNcMJFM1FF5IrBIrhOdhi/LgQI2gwQQWTQw="
.